adagene was co-founded by two serial entrepreneurs to power antibody discovery. its aim is to become the leading player in antibody discovery and engineering. it has developed a proprietary dynamic precision library (dpl) and is showcasing the power of the library with a unique pipeline of innovative antibody therapeutics that is advancing into clinical trials. adagene previously has raised three series of financing with over $86 million. investors include f-prime capital (formerly fidelity biosciences), eight roads ventures china (formerly fidelity growth partners asia), 6 dimensions capital, gp healthcare capital, sequoia china, and new world tmt. for more information, please visit www.adagene.com.
Company profile
Ticker
ADAG
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ADAG stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
29 Mar 24
424B5
Prospectus supplement for primary offering
29 Mar 24
20-F
2023 FY
Annual report (foreign)
29 Mar 24
6-K
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
29 Mar 24
6-K
Current report (foreign)
9 Feb 24
6-K
Current report (foreign)
16 Jan 24
6-K
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
3 Nov 23
6-K
Current report (foreign)
29 Sep 23
6-K
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
31 Aug 23
UPLOAD
Letter from SEC
11 Jul 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q2 2023
33.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 6 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 4.55 bn |
Total shares | 14.73 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
JSR | 5.34 mm | $0.00 |
WuXi PharmTech Healthcare Fund I | 5.28 mm | $42.62 mm |
SC CHINA HOLDING | 1.34 mm | $1.99 bn |
FMR | 1.12 mm | $1.60 bn |
Artal | 1.00 mm | $1.48 mm |
BosValen Asset Management | 292.24 k | $432.51 mm |
General Atlantic | 264.00 k | $390.72 mm |
MS Morgan Stanley | 55.27 k | $81.80 mm |
Renaissance Technologies | 18.40 k | $27.00 k |
Geode Capital Management | 10.31 k | $14.64 mm |
News
12 Health Care Stocks Moving In Monday's Intraday Session
1 Apr 24
Adagene Announced Progress, Expansion Of The Clinical Collaboration Development Program For Its Masked, Anti-CTLA-4 SAFEbody, ADG126 In Combination With Merck's Keytruda (Pembrolizumab), In Patients With Metastatic Microsatellite-stable Colorectal Cancer
9 Feb 24
12 Health Care Stocks Moving In Thursday's After-Market Session
1 Feb 24
Press releases
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
29 Mar 24
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
7 Mar 24
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
9 Feb 24